Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$771.89K$771.89Kderived−73.4% vs Q4 2017 Net Income-$12.20M-$12.20MderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$12,413,646N/M Operating Cash Flowderived-$8,394,184N/M Free Cash Flowderived-$9,656,960N/M Margins · derivedOperating margin-1608.2%−1507.9 pt vs Q4 2017
Net margin-1580.5%−1360.9 pt vs Q4 2017
ended Sep 30, 2018 · filed Dec 18, 2018 · 79 d after period end